Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin. / Lauridsen, Mette Høj; Boesgaard, Trine Welløv; Pedersen, Oluf; Hansen, Torben; Hertz, Birgitte.

In: Ugeskrift for læger, Vol. 171, No. 23, 2009, p. 1923-4.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Lauridsen, MH, Boesgaard, TW, Pedersen, O, Hansen, T & Hertz, B 2009, 'Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin', Ugeskrift for læger, vol. 171, no. 23, pp. 1923-4.

APA

Lauridsen, M. H., Boesgaard, T. W., Pedersen, O., Hansen, T., & Hertz, B. (2009). Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin. Ugeskrift for læger, 171(23), 1923-4.

Vancouver

Lauridsen MH, Boesgaard TW, Pedersen O, Hansen T, Hertz B. Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin. Ugeskrift for læger. 2009;171(23):1923-4.

Author

Lauridsen, Mette Høj ; Boesgaard, Trine Welløv ; Pedersen, Oluf ; Hansen, Torben ; Hertz, Birgitte. / Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin. In: Ugeskrift for læger. 2009 ; Vol. 171, No. 23. pp. 1923-4.

Bibtex

@article{e52d087071fa11de8bc9000ea68e967b,
title = "Spaedb{\o}rnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin",
abstract = "A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1",
author = "Lauridsen, {Mette H{\o}j} and Boesgaard, {Trine Well{\o}v} and Oluf Pedersen and Torben Hansen and Birgitte Hertz",
note = "Keywords: Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Insulin; Mutation; Potassium Channels, Inwardly Rectifying; Treatment Outcome",
year = "2009",
language = "Dansk",
volume = "171",
pages = "1923--4",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "23",

}

RIS

TY - JOUR

T1 - Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin

AU - Lauridsen, Mette Høj

AU - Boesgaard, Trine Welløv

AU - Pedersen, Oluf

AU - Hansen, Torben

AU - Hertz, Birgitte

N1 - Keywords: Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Insulin; Mutation; Potassium Channels, Inwardly Rectifying; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1

AB - A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1

M3 - Tidsskriftartikel

C2 - 19500515

VL - 171

SP - 1923

EP - 1924

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 23

ER -

ID: 13206379